Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006
| العنوان: | Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006 |
|---|---|
| المؤلفون: | Jianmin Long, Jacob Schachter, Ewan Brown, Antoni Ribas, Laurent Mortier, Christoph Hoeller, Scot Ebbinghaus, Adil Daud, Nageatte Ibrahim, Omid Hamid, A. Arance, Marcus O. Butler, Caroline Robert, Euan Walpole, F. Stephen Hodi |
| المصدر: | British Journal of Cancer |
| بيانات النشر: | Springer Science and Business Media LLC, 2018. |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | Cancer Research, medicine.medical_specialty, business.industry, Melanoma, Mucosal melanoma, Ipilimumab, Pembrolizumab, Brief Communication, medicine.disease, Gastroenterology, Clinical trial, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Oncology, 030220 oncology & carcinogenesis, Internal medicine, Post-hoc analysis, Monoclonal, medicine, Skin cancer, business, Survival analysis, medicine.drug |
| الوصف: | Background Mucosal melanoma is an aggressive melanoma with poor prognosis. We assessed efficacy of pembrolizumab in patients with advanced mucosal melanoma in KEYNOTE-001 (NCT01295827), −002 (NCT01704287), and −006 (NCT01866319). Methods Patients received pembrolizumab 2 mg/kg every 3 weeks (Q3W) or 10 mg/kg Q2W or Q3W. Response was assessed by independent central review per RECIST v1.1. Results 1567 patients were treated and 84 (5%) had mucosal melanoma. Fifty-one of 84 were ipilimumab-naive. In patients with mucosal melanoma, the objective response rate (ORR) was 19% (95% CI 11–29%), with median duration of response (DOR) of 27.6 months (range 1.1 + to 27.6). Median progression-free survival (PFS) was 2.8 months (95% CI 2.7–2.8), with median overall survival (OS) of 11.3 months (7.7–16.6). ORR was 22% (95% CI 11–35%) and 15% (95% CI 5–32%) in ipilimumab-naive and ipilimumab-treated patients. Conclusion Pembrolizumab provides durable antitumour activity in patients with advanced mucosal melanoma regardless of prior ipilimumab. |
| تدمد: | 1532-1827 0007-0920 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d3913aedadc3153cefa63dd2a9ad5beTest https://doi.org/10.1038/s41416-018-0207-6Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....8d3913aedadc3153cefa63dd2a9ad5be |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15321827 00070920 |
|---|